Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms

Ahn

Cancer Chemother Pharmacol

et al. 2012

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 97%

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy

Ahn

Cancer Chemother Pharmacol

et al. 2012

“…Reduced clearance may also lead to accumulation of docetaxel, resulting in an increased risk of docetaxel toxicities such as myelosuppression and FN [25]. Tsai et al has associated certain polymorphisms (patients manifesting ABCB1 2677GG and CYP3A5*1/3 genotypes) to be highly susceptible to FN events during their chemotherapy [26]. Two studies investigating docetaxel toxicities in Asian patients revealed that docetaxel-induced FN rate was high and these observations were congruent to findings in our study [11,24].…”

Section: Discussionsupporting

confidence: 94%

Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy

Chan

Shih

et al. 2010

Support Care Cancer

“…For the CGC haplotype, greater overall survival was reported [119], and for the 2677GG genotype, there were increased risks of certain adverse effects (e.g. fever, pleural effusions and febrile neutropenia) [120]. An increased risk of docetaxel-induced haematological toxicities was also observed among Korean cancer patients with the 3435TT and 2677G/T genotypes [121].…”

Section: Taxanesmentioning

confidence: 92%

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

et al. 2015

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1) is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma membrane of many different cell types. Numerous structurally unrelated compounds, including drugs and environmental toxins, have been identified as substrates. ABCB1 limits the absorption of xenobiotics from the gut lumen, protects sensitive tissues (e.g. the brain, fetus and testes) from xenobiotics and is involved in biliary and renal secretion of its substrates. In recent years, a large number of polymorphisms of the ABCB1 [ATP-binding cassette, sub-family B (MDR/TAP), member 1] gene have been described. The variants 1236C>T (rs1128503, p.G412G), 2677G>T/A (rs2032582, p.A893S/T) and 3435C>T (rs1045642, p.I1145I) occur at high allele frequencies and create a common haplotype; therefore, they have been most widely studied. This review provides an overview of clinical studies published between 2002 and March 2015. In summary, the effect of ABCB1 variation on P-glycoprotein expression (messenger RNA and protein expression) and/or activity in various tissues (e.g. the liver, gut and heart) appears to be small. Although polymorphisms and haplotypes of ABCB1 have been associated with alterations in drug disposition and drug response, including adverse events with various ABCB1 substrates in different ethnic populations, the results have been majorly conflicting, with limited clinical relevance. Future research activities are warranted, considering a deep-sequencing approach, as well as well-designed clinical studies with appropriate sample sizes to elucidate the impact of rare ABCB1 variants and their potential consequences for effect sizes.